Moreover, when 10μM arachidonyl trifluoromethyl ketone (ATK; a cPLA2 inhibitor) is treated in PKCδ deficient B16F10 melanoma, it failed to augment ceramide generation (Figure 4E) and apoptosis (Figure 4F) in cisplatin treated cells. Here, PLA2G4A is linked to melanoma.